These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

855 related items for PubMed ID: 11919304

  • 1. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
    Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ, Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators.
    N Engl J Med; 2002 Mar 28; 346(13):957-66. PubMed ID: 11919304
    [Abstract] [Full Text] [Related]

  • 2. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ.
    N Engl J Med; 1999 Jul 29; 341(5):319-27. PubMed ID: 10423466
    [Abstract] [Full Text] [Related]

  • 3. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
    Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansiéri M, Choussat R, Pinton P, ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up.
    N Engl J Med; 2001 Jun 21; 344(25):1895-903. PubMed ID: 11419426
    [Abstract] [Full Text] [Related]

  • 4. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW, CADILLAC Investigators.
    Circulation; 2003 Sep 16; 108(11):1316-23. PubMed ID: 12939213
    [Abstract] [Full Text] [Related]

  • 5. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Guagliumi G, Stone GW, Cox DA, Stuckey T, Tcheng JE, Turco M, Musumeci G, Griffin JJ, Lansky AJ, Mehran R, Grines CL, Garcia E.
    Circulation; 2004 Sep 21; 110(12):1598-604. PubMed ID: 15353506
    [Abstract] [Full Text] [Related]

  • 6. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L, TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial.
    N Engl J Med; 2001 Jun 21; 344(25):1888-94. PubMed ID: 11419425
    [Abstract] [Full Text] [Related]

  • 7. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial).
    Stuckey TD, Stone GW, Cox DA, Tcheng JE, Garcia E, Carroll J, Guagliumi G, Rutherford BD, Griffin JJ, Turco M, Lansky AJ, Mehran R, Fahy M, Brodie BR, Grines CL, CADILLAC investigators.
    Am J Cardiol; 2005 Jan 01; 95(1):1-7. PubMed ID: 15619385
    [Abstract] [Full Text] [Related]

  • 8. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.
    Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari R, STRATEGY Investigators.
    JAMA; 2005 May 04; 293(17):2109-17. PubMed ID: 15870414
    [Abstract] [Full Text] [Related]

  • 9. Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial.
    Cox DA, Stone GW, Grines CL, Stuckey T, Cohen DJ, Tcheng JE, Garcia E, Guagliumi G, Iwaoka RS, Fahy M, Turco M, Lansky AJ, Griffin JJ, Mehran R, CADILLAC Investigators.
    J Am Coll Cardiol; 2003 Sep 17; 42(6):971-7. PubMed ID: 13678914
    [Abstract] [Full Text] [Related]

  • 10. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.
    Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ.
    Circulation; 1998 Aug 25; 98(8):734-41. PubMed ID: 9727542
    [Abstract] [Full Text] [Related]

  • 11. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators.
    Schömig A, Kastrati A, Dirschinger J, Mehilli J, Schricke U, Pache J, Martinoff S, Neumann FJ, Schwaiger M.
    N Engl J Med; 2000 Aug 10; 343(6):385-91. PubMed ID: 10933737
    [Abstract] [Full Text] [Related]

  • 12. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone.
    Antoniucci D, Migliorini A, Parodi G, Valenti R, Rodriguez A, Hempel A, Memisha G, Santoro GM.
    Circulation; 2004 Apr 13; 109(14):1704-6. PubMed ID: 15066943
    [Abstract] [Full Text] [Related]

  • 13. Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty.
    Al Suwaidi J, Holmes DR, Salam AM, Lennon R, Berger PB.
    Am Heart J; 2004 May 13; 147(5):815-22. PubMed ID: 15131536
    [Abstract] [Full Text] [Related]

  • 14. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
    Marso SP, Lincoff AM, Ellis SG, Bhatt DL, Tanguay JF, Kleiman NS, Hammoud T, Booth JE, Sapp SK, Topol EJ.
    Circulation; 2004 May 13; 100(25):2477-84. PubMed ID: 10604884
    [Abstract] [Full Text] [Related]

  • 15. Combination of abciximab with primary stenting in patients with acute myocardial infarction: a community hospital experience.
    Arjomand H, Mascarenhas DA.
    J Invasive Cardiol; 2000 Mar 13; 12(3):125-9. PubMed ID: 10731278
    [Abstract] [Full Text] [Related]

  • 16. Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting.
    Jeremias A, Vasu S, Gruberg L, Kastrati A, Stone GW, Brown DL.
    Catheter Cardiovasc Interv; 2010 May 01; 75(6):895-902. PubMed ID: 20088008
    [Abstract] [Full Text] [Related]

  • 17. Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI).
    Di Mario C, Bolognese L, Maillard L, Dudek D, Gambarati G, Manari A, Guiducci V, Patrizi G, Rusconi LC, Piovaccari G, Hibon AR, Belpomme V, Indolfi C, Olivari Z, Steffenino G, Zmudka K, Airoldi F, Panzarasa R, Flather M, Steg PG.
    Am Heart J; 2004 Sep 01; 148(3):378-85. PubMed ID: 15389222
    [Abstract] [Full Text] [Related]

  • 18. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.
    Circulation; 1999 Apr 20; 99(15):1951-8. PubMed ID: 10208997
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial.
    Bakhai A, Stone GW, Grines CL, Murphy SA, Githiora L, Berezin RH, Cox DA, Stuckey T, Griffin JJ, Tcheng JE, Cohen DJ, CADILLAC Investigators.
    Circulation; 2003 Dec 09; 108(23):2857-63. PubMed ID: 14610016
    [Abstract] [Full Text] [Related]

  • 20. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schömig A, Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators.
    N Engl J Med; 2004 Jan 15; 350(3):232-8. PubMed ID: 14724302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.